Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms
Endometrial Cancer

Interventions

DRUG: Relacorilant 150 mg once daily (QD)
DRUG: Nab-paclitaxel 80 mg/m^2
DRUG: Bevacizumab 10 mg/kg

Sponsor

Corcept Therapeutics